Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Goldfinch Bio Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are being handled by 2 distinct examiners and are situated in 2 distinct art units. This distribution suggests that the company's active filings cover different technical niches within the broader biotechnology field. A decentralized approach like this requires the applicant to adapt to multiple procedural environments.
BARSKY, JARED is the busiest examiner for this portfolio, overseeing 1 pending office action. This represents 1 of the 2 pending office actions currently active for the company. The involvement of multiple examiners across separate art units requires a prosecution approach that accounts for the specific examination cultures of different patent office divisions. Success in the Biotechnology & Pharmaceuticals field will depend on effective communication with both assigned officials.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 1 | 50.2% | +22.9% |
| HASTINGS, ALISON AZAR | 1 | 62.6% | +40.3% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 16636606 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | HASTINGS, ALISON AZAR | 2d overdue |
| 17766492 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | BARSKY, JARED | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1627 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17766492 | BIOMARKER-BASED TREATMENT OF FOCAL SEGMENTAL GLOMERULOSCLEROSIS AND DIABETIC KIDNEY DISEASE | BARSKY, JARED | 1628 | DP | Final Rejection | — | Pending | Apr 04, 2022 |
| 16636606 | BENZIMIDAZOLES AND AZA-BENZIMIDAZOLES, AND METHODS OF USE THEREOF | HASTINGS, ALISON AZAR | 1627 | §102 | Final Rejection | 2d overdue | Pending | Feb 04, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialGoldfinch Bio Inc. has 2 pending office actions as of November 2026, spread across 2 art units and 2 examiners.
Jared Barsky has the most, with 1 of Goldfinch Bio Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.